Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 14/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $281.77MP/E 5.0Yield –
Elite Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Elite Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 25.3%. For fiscal 2026 it was 33.0%, against 23.3% the year before. The highest annual figure on record is 33.0% in fiscal 2026.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 33.0% | +9.7 |
| FY2025 | Mar 31, 2025 | 23.3% | +4.3 |
| FY2024 | Mar 31, 2024 | 19.1% | +8.3 |
| FY2023 | Mar 31, 2023 | 10.8% | −5.0 |
| FY2022 | Mar 31, 2022 | 15.7% | +7.4 |
| FY2021 | Mar 31, 2021 | 8.3% | +21.0 |
| FY2020 | Mar 31, 2020 | -12.7% | +108.3 |
| FY2019 | Mar 31, 2019 | -121.0% | +0.3 |
| FY2018 | Mar 31, 2018 | -121.4% | −45.0 |
| FY2017 | Mar 31, 2017 | -76.3% | −9.8 |
| FY2016 | Mar 31, 2016 | -66.5% | +262.6 |
| FY2015 | Mar 31, 2015 | -329.1% | −214.3 |
| FY2014 | Mar 31, 2014 | -114.8% | −68.9 |
| FY2013 | Mar 31, 2013 | -45.9% | +35.2 |
| FY2012 | Mar 31, 2012 | -81.1% | −60.3 |
| FY2011 | Mar 31, 2011 | -20.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | 24.8% | +2.1 |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | 23.3% | −30.7 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | 25.0% | −9.9 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | 28.5% | +20.9 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | 22.6% | +4.2 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | 54.0% | +33.4 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | 34.9% | +14.1 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | 7.6% | −15.1 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | 18.5% | +4.9 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | 20.6% | +2.7 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | 20.8% | +25.3 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | 22.7% | +1.6 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | 13.6% | +1.0 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | 17.8% | +4.5 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -4.5% | −15.6 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | 21.2% | +0.8 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | 12.6% | −4.0 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | 13.3% | −0.3 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | 11.1% | +35.4 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | 20.4% | +3.8 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | 16.6% | −1.5 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | 13.7% | +2.7 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -24.3% | +3.5 |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | 16.6% | +2.9 |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | 18.1% | +27.9 |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | 11.0% | +45.2 |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -27.8% | +121.8 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | 13.7% | +111.6 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -9.8% | +184.8 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -34.2% | +51.6 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -149.6% | +14.7 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -97.9% | −16.7 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -194.6% | −63.5 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -85.7% | +45.7 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -164.2% | +72.1 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -81.2% | −7.3 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -131.2% | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -131.4% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -236.3% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -73.9% | – |
See a number that looks wrong?